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Background. Histoplasmosis is a common cause of invasive fungal infection in endemic regions and accurate diagnosis is
difficult without direct tissue culture or pathology. Indirect fungal antigen testing for various fungal pathogens are typically
performed to assist with diagnostic workup, though cross-reaction can lead to difficulty in interpreting results. We aimed to
compare indirect fungal diagnostic tests and evaluate prevalence of positive antigen testing for non-Histoplasma fungal
pathogens in patients with proven histoplasmosis.
Methods. We performed a single-center retrospective review of adult patients with proven histoplasmosis diagnosed by fungal
culture and/or cytology from January 2010 to March 2018. Patient demographics, clinical characteristics, and results of fungal
antigen testing for Histoplasma, Blastomyces, Aspergillus, Cryptococcus, and (1→3)-β-D-glucan were evaluated. Two different
urine Histoplasma antigen assays were used during the study period.
Results. Fifty-seven of 182 (31.3%) patients reviewed had proven histoplasmosis and presented with acute pulmonary (n = 10),
chronic pulmonary (n = 7), and disseminated (n = 40) disease. Forty-one (72%) of these patients were immunosuppressed. Urine
Blastomyces antigen (93%) and serum (1→3)-β-D-glucan (88%) were commonly positive in patients with histoplasmosis, whereas
Aspergillus antigen was detected in 50% of patients and Cryptococcus antigenemia was rare (5%). In patients with disseminated
disease, the MiraVista urine Histoplasma antigen assay had higher sensitivity than the Viracor urine Histoplasma antigen assay
(86% vs 50%, respectively; P = .019).
Conclusions. Noninvasive fungal antigen assays are helpful diagnostic tools; however, given their low specificity, clinicians
must be aware of the various clinical presentations of invasive fungal infections and be aware of the limitations of these tests.
Keywords. cross-reactivity; fungal diagnostics; histoplasmosis; urine Histoplasma antigen.
Histoplasmosis, infection with Histoplasma capsulatum, is an
endemic fungal infection frequently seen in the central and
eastern United States (US), especially around the Ohio and
Mississippi river valleys [1]. Histoplasmosis has a wide spec
trum of presentation ranging from isolated pulmonary disease
to disseminated infection that can involve fungemia, central
nervous system (CNS) infection, bone marrow infiltration,
and other organ involvement [2, 3].
The gold standard method for diagnosis of proven histoplas
mosis is by either isolation of Histoplasma capsulatum from
fungal culture or identification of histopathological findings
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consistent with this organism from clinical specimens [4].
However, diagnosis is challenging as invasive sampling of ap
propriate tissue can be difficult and fungal culture results can
take weeks [5]. Consequently, more rapid indirect markers
are frequently used, such as Histoplasma antigen or antibody
testing in urine, serum, cerebrospinal fluid (CSF), and other
clinical specimens [5–7]. The first noninvasive antigen assay
was developed in 1986, providing a novel, sensitive, and rapid
alternative for Histoplasma testing [5]. Newer-generation en
zyme immunoassays are now available [8–10]. The urine
Histoplasma antigen test has proven to be quite sensitive in dis
seminated disease with various studies showing 89%–92%, but
less sensitive in limited forms of infection [11–14]. However,
cross-reaction with other invasive fungal pathogens has result
ed in unreliable specificity [15–17]. Due to rapid turnaround
time, decreased need for invasive sampling, and adequate sen
sitivity, antigen testing remains a preferred testing modality for
histoplasmosis.
Other invasive fungal infections are routinely diagnosed with
urine or serum antigen testing [4, 5, 18, 19]. Simultaneous
Histoplasma, Blastomyces, Cryptococcus, Aspergillus, and serum
(1→3)-β-D-glucan antigen testing is commonly performed to
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METHODS
Study Design

We performed a single-center retrospective chart review of
adult patients from January 2010 to March 2018 diagnosed
with proven histoplasmosis at the University of Arkansas for
Medical Sciences (UAMS), a tertiary care academic center
with a wide catchment area. Patients were considered proven
cases if they had evidence of histoplasmosis by positive culture
for Histoplasma or cytological examination revealing an organ
ism consistent with Histoplasma. International Classification of
Diseases, Ninth Revision codes and microbiological culture data
were used to identify potential patients. Patients with a positive
Histoplasma antigen test without evidence of histoplasmosis on
culture or tissue cytology were considered probable cases and
not included in further analysis. Patients with an invasive fun
gal infection other than histoplasmosis were planned to be ex
cluded; however, there were no patients in this cohort with a
proven invasive fungal infection other than histoplasmosis.
Patients were also excluded if they had a previous diagnosis
of histoplasmosis or if they were only diagnosed with presumed
ocular histoplasmosis syndrome.
Data Collection

Data were collected on patient demographics and comorbid
medical conditions including diabetes mellitus, hepatic cirrhosis,
human immunodeficiency virus (HIV), AIDS, end-stage renal
disease, active malignancy, and immunosuppression. Stages of
histoplasmosis (acute pulmonary, chronic pulmonary, and dis
seminated) were determined based on chart review of discharge
diagnoses set by the treating infectious diseases physician. Chart
review was performed by medical trainees (G. K. and M. P.) and
an infectious diseases attending physician (R. D.). Culture re
sults, pathology results, and fungal laboratory data including
urine Histoplasma antigen, serum Histoplasma antigen, CSF
2 • OFID • Krishnan et al

Histoplasma antigen, respiratory Histoplasma antigen, serum
Histoplasma antibodies, CSF Histoplasma antibodies, urine
Blastomyces antigen, respiratory Blastomyces antigen, serum
(1→3)-β-D-glucan, serum cryptococcal antigen, CSF cryptococ
cal antigen, and serum Aspergillus antigen (galactomannan) were
collected.
Fungal Antigen Testing

During the study period, Blastomyces antigen testing was per
formed by MiraVista Laboratories (Indianapolis, Indiana),
Aspergillus antigen immunoenzymatic sandwich microplate
assay was performed by Bio-Rad (Hercules, California), serum
(1→3)-β-D-glucan assay was performed by Viracor Laboratory
(Lenexa, Kansas), and Histoplasma antigen testing was per
formed by Viracor Laboratory (Lenexa, Kansas) during
January 2010–February 2015 and MiraVista Laboratory
(Indianapolis, Indiana) during March 2015–March 2018. The
Cryptococcus antigen testing was performed at UAMS using
the lateral flow assay produced by Immy Corporation
(Norman, Oklahoma). Fungal cultures were performed by plat
ing specimen on both blood heart infusion agar and potato dex
trose agar. Identification of fungal isolates was performed using
matrix-assisted laser desorption/ionization–time-of-flight
mass spectrometry using VITEK MS (bioMérieux). Direct ex
amination of tissue for identification by pathology includes
both hematoxylin and eosin stain and Grocott methenamine
silver stain.
Definitions

Comorbidities were determined by their presence in medical
record. AIDS was defined as having CD4 <200 cells/µL in the
presence of HIV diagnosis. Immunosuppressive medications
included chemotherapy, immunotherapy, being on a cortico
steroid equivalent of oral prednisone ≥20 mg for >2 weeks,
or being on other known immunosuppressive medications.
Stage of histoplasmosis infection was determined by either doc
umentation of stage by the treating infectious diseases physi
cian in the medical record or by chart review.
Acute pulmonary histoplasmosis was defined as a pulmo
nary infection with acute onset of symptoms associated with
heavy inhalation exposure to airborne Histoplasma spores.
Chronic pulmonary histoplasmosis was defined as a chronic
pulmonary disease, which can follow acute pulmonary histo
plasmosis and is characterized by low-grade chronic pulmo
nary symptoms, lung cavitation, pulmonary fibrosis, and
progressive pulmonary insufficiency. Progressive disseminated
histoplasmosis or disseminated histoplasmosis was defined as a
progressive extrapulmonary infection characterized most com
monly by fever, fatigue, and weight loss, among other symp
toms, depending on the organ system affected [2, 3]. Proven
histoplasmosis was diagnosed in a host with illness consistent
with histoplasmosis and (1) recovery in culture from specimen
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evaluate at-risk patients who present with a clinical syndrome
suspicious for invasive fungal disease. Interpretation of results
can be difficult when multiple antigens are detected concur
rently, in geographic locations with multiple endemic fungi
[20, 21], and when invasive testing to obtain tissue cannot be
safely performed or is delayed. There are many studies evaluat
ing the performance of Histoplasma antigen and antibody tests
[5, 11–14, 17]; however, there are limited published data on
positive rates of non-Histoplasma fungal antigen tests in prov
en histoplasmosis.
The primary aim of this study was to determine the rate of
positivity of various non-Histoplasma fungal antigen tests in
patients with proven histoplasmosis to better understand crossreaction of these other antigen assays. Sensitivity of urine
Histoplasma antigen testing in our center’s experience was
also assessed.

obtained from affected site or from blood or (2) histopathologic
or direct microscopic demonstration of morphologic forms
consistent with Histoplasma [4].

Table 1. Demographic Details of the Patients With Proven Histoplasmosis
Proven Histoplasmosis
(n = 57)

Characteristics
Sex, female

Statistical Analyses

RESULTS

50.1 ± 18.6

Race
White

35 (61.4)

African American

19 (33.3)

Asian

1 (1.8)

Other

2 (3.5)

Comorbidity
Diabetes mellitus

Fifty-seven of 182 (31.3%) patients diagnosed with histoplas
mosis during the study period had definitive proof of histoplas
mosis with either positive fungal cultures (30 [52.6%]),
characteristic findings on histopathologic examination
(12 [21.1%]), or both (15 [26.3%]) and met inclusion criteria
for proven histoplasmosis. The majority of remaining cases
were diagnosed with antigen testing alone and thus not includ
ed in further analysis.
Cases were predominantly male (56.1%), with a mean age of
50.1 ± 18.6 years. White race (61.4%) was more common than
other races. Seventy-two percent of this patient population was
considered immunosuppressed. Patient demographics are list
ed in Table 1.
Of the 57 patients with proven histoplasmosis, 10 (17.5%)
had acute pulmonary, 7 (12.3%) had chronic pulmonary, and
40 (70.2%) had disseminated disease. One patient with dissem
inated histoplasmosis had evidence of CNS infection. There
were 40 patients with disseminated histoplasmosis, of which
36 (90%) had an obvious immunodeficiency. Out of the 36,
19 patients had HIV/AIDS, 15 were on immunosuppressive
medicines (4 with history of solid organ transplant; 3 with ma
lignancy; others for autoimmune diseases), 1 had malignancy
not on immunosuppressive medicines, and 1 had cirrhosis.
Four others had no obvious or known immunodeficiency.
Table 2 shows results of indirect fungal testing in the includ
ed patients. Urine Histoplasma antigen was positive in 30 of 46
(65%) patients tested though positivity rate differed between
Viracor (8/18 [44%]) and MiraVista (22/28 [79%]) assays
(P = .017). MiraVista assay was positive in 18 of 21 (86%) pa
tients with disseminated disease, 4 of 5 (80%) with acute pul
monary disease, and 0 of 2 (0%) with chronic pulmonary
disease. Serum Histoplasma antigen was tested in 3 patients,
and all were negative. CSF Histoplasma antigen was tested in
1 patient, and it was positive. Respiratory or bronchoalveolar
lavage Histoplasma antigen was not tested in any patients.
Serum Histoplasma antibody was tested in 8 patients, of which
5 were positive and 3 were negative. CSF Histoplasma antibod
ies were tested in 2 patients and 1 was positive. The patient with
positive CSF Histoplasma antigen and CSF Histoplasma anti
body had evidence of CNS disease along with disseminated dis
ease and was classified under disseminated histoplasmosis.

9 (15.7)

Congestive heart failure
ESRD

4 (7)
5 (8.7)

Hepatic cirrhosis

4 (7)

Hepatitis B

2 (3.5)

Hepatitis C

2 (3.5)

HIV

20 (35)

Immunosuppresseda

41 (72)

AIDS

18 (31.5)

Malignancy

6 (10.5)

History of solid organ transplant
Immunosuppressive medicationsb

5 (8.7)
21 (36.8)

Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ESRD, end-stage renal disease; HIV, human immunodeficiency virus; SD,
standard deviation.
a

Total number of immunosuppressed patients. Some patients may have >1 reason to be
considered immunosuppressed.

b

Immunosuppressive medications included chemotherapy, immunotherapy, being on a
corticosteroid equivalent of oral prednisone ≥20 mg for >2 weeks, or being on other
known immunosuppressive medications.

Urine Blastomyces antigen was positive in 26 of 33 (79%) pa
tients tested with proven histoplasmosis showing high crossreactivity with urine Histoplasma antigen. This cross-reaction
was most profound in disseminated disease, with 25 of 27
(93%) testing positive (Table 2). Serum Blastomyces antigen,
CSF Blastomyces antigen, and respiratory Blastomyces antigen
were not tested in any patients. Serum (1→3)-β-D-glucan, serum
Aspergillus antigen, and serum Cryptococcus antigen were posi
tive in 21 of 28 (75%), 13 of 26 (50%), and 1 of 22 (5%) patients
with proven histoplasmosis, respectively (Table 2). The 1 patient
with positive serum cryptococcal antigen had AIDS (CD4 1
cell/mL) with multiple positive fungal blood cultures for
Histoplasma and tested positive for urine Histoplasma antigen.
Fungal blood and CSF cultures never revealed Cryptococcus,
and CSF cryptococcal antigen was negative on this patient.
Specificity in the setting of proven histoplasmosis is very low
for urine Blastomyces antigen (21%), serum Aspergillus antigen
(50%), and serum (1→3)-β-D-glucan (25%). However, specific
ity of serum Cryptococcus antigen in the setting of proven his
toplasmosis was 96%.
DISCUSSION

This is the largest single-center retrospective study in the US
looking at various fungal antigen assays in the setting of proven
Fungal Diagnostics in Histoplasmosis • OFID • 3
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The χ2 and Fisher exact tests were used for comparative analysis
were appropriate. All statistical analyses were performed using
Stata software version 14.1 (StataCorp, College Station, Texas).

25 (43.9)

Age, y, mean ± SD

Table 2. Analysis of Various Fungal Antigen Testing in the Setting of Proven Histoplasmosis
Proven Histoplasmosis
(n = 57)

Serum
Urine Histoplasma Antigena Urine Blastomyces Antigen Serum Cryptococcus Antigen Serum Aspergillus Antigen (1→3)-β-D-Glucan
4/5 (80)
0/0 (…)
4/5 (80)

1/2 (50)

0/1 (0)

1/4 (25)

0/2 (0)

Chronic pulmonary (n = 7)
Viracor
MiraVista

0/4 (0)
0/2 (0)
0/2 (0)

0/4 (0)

0/2 (0)

0/2 (0)

0/2 (0)

Disseminated (n = 40)
Viracor
MiraVista (P = .019)b

26/37 (70)
8/16 (50)
18/21 (86)

25/27 (93)

1/19 (5)

12/20 (60)

21/24 (88)

Total
Viracor
MiraVista (P = .017)b

30/46 (65)
8/18 (44)
22/28 (79)

26/33 (79)

1/22 (5)

13/26 (50)

21/28 (75)

Data are presented as No. (%) unless otherwise indicated.
a

During the study period, reference testing for urine Histoplasma antigen testing transitioned from Viracor to MiraVista assay in March 2015.

b 2

χ analysis performed comparing Viracor to MiraVista assays.

histoplasmosis and comparing sensitivity of urine Histoplasma
antigen by different laboratories over a period of 9 years. Per
the Centers for Disease Control and Prevention, >60% of peo
ple in the US who live in areas surrounding the Ohio and
Mississippi river valleys have evidence of exposure to
Histoplasma during their lifetime [1]. Both histoplasmosis
and blastomycosis are endemic to Arkansas, while coccidioido
mycosis is not [22]. However, progressive disseminated histo
plasmosis is most common among immunosuppressed
individuals, especially patients with HIV/AIDS [23, 24].
Immunosuppressed patients are prone to other fungal infec
tions; thus, sensitive and specific tests are crucial to identify
and distinguish these infections in at-risk populations [25].
Other conventional diagnostic tests such as radiological imag
ing also fail to specifically identify fungal pathogens at the or
ganism level, and fungal cultures can take long time to result
[4, 18]. Invasive diagnostic methods cannot always be safely
performed in this population to get tissue diagnosis due to
risk of complications including bleeding, risk of respiratory
failure, high risk with anesthesia, etc [19]. Thus, use of nonin
vasive fungal antigen testing can assist with diagnosis of fungal
infections.
Herein, we showed frequent cross-reaction of
non-Histoplasma fungal antigen tests in patients with proven
histoplasmosis. There was a high rate of cross-reaction with
urine Blastomyces antigen, which can be confusing in regions
where both pathogens coexist, such as the Ohio and
Mississippi river valleys in the US [26]. Our study also showed
that urine Blastomyces antigen test was more sensitive for diag
nosis of proven histoplasmosis than the Viracor urine
Histoplasma antigen test designed for this pathogen. This study
shows high false-positive rates of other fungal antigen tests in
the setting of proven histoplasmosis including urine
Blastomyces antigen (79%) and serum Aspergillus antigen
(50%) as these patients did not have proven coexisting fungal
4 • OFID • Krishnan et al

infections. Serum (1→3)-β-D-glucan, a common nonspecific
fungal biomarker, was also frequently found to be positive
(75%) in patients with proven histoplasmosis. There was even
1 patient with proven histoplasmosis who had a positive serum
Cryptococcus antigen. While active concomitant cryptococcal
infection cannot be completely ruled out, blood and CSF fungal
cultures did not identify Cryptococcus and CSF cryptococcal
antigen was negative. Although from a diagnostic perspective
this adds to the provider’s dilemma, recommended guidelines
for management are very similar for histoplasmosis and blasto
mycosis, making less clinical impact. But this cannot be said for
infections caused by organisms such as Aspergillus and
Cryptococcus, where treatment guidelines are different and dis
tinctive diagnosis is important. While noninvasive fungal anti
gen tests are helpful in diagnosis of these infrequent infections,
clinicians must still maintain knowledge of the clinical differ
ences between various fungal pathogens and be aware of the
limitations of these tests and make the diagnosis based on the
right clinical setting and exposure.
This study highlights the performance variability between
commercial Histoplasma urine antigen testing as the sensitivi
ties of the 2 assays utilized during this study period were quite
disparate (79% vs 44%). Although fungal antigen assays have
evolved over the past decades, more work needs to be done
to develop sensitive and specific tests. The lack of specificity
and cross-reactivity have been considered to be a consequence
of the tests recognizing common polysaccharide moieties in
these fungal antigens [15]. While there is significant
paucity of previous literature to compare performance of
non-Histoplasma antigen tests in the setting of proven histo
plasmosis, smaller studies and case reports have reported sim
ilar cross-reactivity [27, 28]. In 1 study, serum Aspergillus
galactomannan assay was positive in 73% patients with dissem
inated histoplasmosis [27, 28], while another study showed
urine Blastomyces antigen cross-reactivity in 95.6% of patients
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Acute pulmonary (n = 10)
Viracor
MiraVista

function tests. Interestingly, patients with disseminated histo
plasmosis can have elevated aspartate aminotransferase to ala
nine aminotransferase ratio [34]. Histopathology of the
affected tissue, or fungal blood culture, is the gold standard
and can often isolate small, budding, intracellular yeast forms
in macrophages [4]. The clinical presentations of disseminated
blastomycosis are highly variable. While lung is the primary fo
cus of infection, blastomycosis can present as cutaneous lesions
ranging from nodules and verrucous lesions to ulcers, osseous
lesions in the form of osteomyelitis, genitourinary infections
like prostatitis, and even CNS infections [35]. Workup should
include urine Blastomyces antigen and serum Blastomyces anti
bodies. Pathology and culture are, again, gold standard and typ
ical broad-based budding yeast forms are characteristic [4].
Invasive pulmonary aspergillosis, on the other hand, is the
most common invasive fungal infection of the lung in immuno
compromised hosts, especially stem cell transplant recipients.
Hematogenous dissemination is often fatal with thrombosis,
hemorrhagic infarction, end organ damage and vascular inva
sion [36]. Cryptococcosis, on the other hand, can present as
acute, subacute, or chronic pulmonary infection; meningitis
(most common in immunocompromised hosts, especially pa
tients with advanced HIV/AIDS); and cutaneous manifesta
tion, which is usually in the form of raised nodules with
umbilicated centers [37]. Given the wide range of presentations
as mentioned above, the clinical scenario should dictate which
diagnostic tests are ordered in a patient, and interpretation of
results should be based on the pretest probability gleaned
from clinical presentation. Providers should avoid ordering
multiple fungal diagnostic tests in order to avoid confusion
and to reduce cost. Lastly, providers should be aware of areas
of epidemiological overlap with histoplasmosis and blastomy
cosis, and differences in their clinical presentation. While these
noninvasive assays are helpful diagnostic tools, clinicians
should be aware of their low specificity.
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